Bio/Pharma Business

Ipsen to Bolster Liver Disease Portfolio with Albireo Acquisition

January 11, 2023

Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.

Sartorius and RoosterBio Strike Downstream Collaboration Deal

January 11, 2023

Sartorius and RoosterBio will work together to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies.

Moderna and CytomX Announce mRNA Partnership

January 10, 2023

The collaboration will see Moderna and CytomX work together to develop mRNA-based conditionally activated therapeutics.

Astrea Bioseparations Acquires Delta Precision

January 09, 2023

Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for biomanufacturing.

Avantor and Catalent Enter Multi-Year Agreement

January 09, 2023

Avantor and Catalent have entered into a multi-year supply and services agreement.

Agilent Acquires Life Sciences Company Avida Biomed

January 04, 2023

Agilent’s acquisition of Avida grants them access to high-performance enrichment workflows that enable NGS approaches for studying cancer.

Merck Licenses Kelun-Biotech ADC’s in Deal Worth $9.3 Billion

January 04, 2023

Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.

Crossing the Same River Multiple Times

January 03, 2023

Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.

Predicting Pharma’s Future

January 03, 2023

Experts weigh in on trends in the biotechnology market, psychedelics, and India.

Pedestrians as Priority

January 02, 2023

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”